Cypress Capital’s Lantern Pharma LTRN Stock Holding History

Cypress Capital’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-200	Closed	-$934	–	234
2024 Q2	$934	Buy	+200	New	+$1.2K	﹤0.01%	330

Other funds holding LTRN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Cypress Capital's LTRN Position: Q3 2024 in Review

Cypress Capital sold out of Lantern Pharma (LTRN) in Q3 2024, closing a stake of 200 shares — an estimated $934 sold.

Cypress Capital first reported a position in LTRN in Q2 2024 and held it in 1 quarter. The position peaked at $934 in Q2 2024. 31 funds tracked by Wall St. Rank hold LTRN as of Q3 2024.

Cypress Capital reported no remaining Lantern Pharma position as of Q3 2024 after selling out during the quarter.
Cypress Capital sold 200 Lantern Pharma shares in Q3 2024, an estimated $934.
Cypress Capital first reported a position in Lantern Pharma in Q2 2024 and held it in 1 quarter.
Cypress Capital's Lantern Pharma position peaked at $934 in Q2 2024.
31 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2024.

Based on Cypress Capital's 13F filing for Q3 2024, filed 12 Nov 2024.